Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy

Published on 04 Jun 2025
Last Updated on 04 Jun 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended epcoritamab for inclusion on the MOH List of Subsidised Drugs for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. The decision for epcoritamab was based on the uncertainties surrounding its magnitude of clinical benefit, unfavourable cost-effectiveness compared with chemotherapy, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for epcoritamab are provided in the Annex.

Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy (Published 4 Jun 2025)

PES_Epcoritamab for previously treated relapsed or refractory diffuse large B-cell lymphoma (Published 4 Jun 2025)